abrdn plc Makes New $13.16 Million Investment in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

abrdn plc acquired a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 237,965 shares of the specialty pharmaceutical company's stock, valued at approximately $13,155,000. abrdn plc owned about 1.13% of ANI Pharmaceuticals at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of ANIP. Pacer Advisors Inc. lifted its stake in ANI Pharmaceuticals by 23,259.8% in the third quarter. Pacer Advisors Inc. now owns 568,343 shares of the specialty pharmaceutical company's stock valued at $33,907,000 after buying an additional 565,910 shares during the last quarter. JPMorgan Chase & Co. raised its position in ANI Pharmaceuticals by 159.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company's stock valued at $33,101,000 after purchasing an additional 340,854 shares during the last quarter. Bank of Montreal Can acquired a new stake in ANI Pharmaceuticals during the 3rd quarter worth $13,043,000. Mizuho Markets Americas LLC purchased a new position in ANI Pharmaceuticals during the 3rd quarter worth $11,670,000. Finally, Barclays PLC increased its stake in ANI Pharmaceuticals by 1,681.2% in the third quarter. Barclays PLC now owns 143,033 shares of the specialty pharmaceutical company's stock valued at $8,534,000 after purchasing an additional 135,003 shares during the period. Institutional investors and hedge funds own 76.05% of the company's stock.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ:ANIP traded up $0.26 during trading on Tuesday, hitting $59.85. 225,486 shares of the stock were exchanged, compared to its average volume of 190,814. The company has a market cap of $1.26 billion, a PE ratio of -108.82 and a beta of 0.74. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. The company has a fifty day moving average price of $56.80 and a two-hundred day moving average price of $58.38. ANI Pharmaceuticals, Inc. has a 12-month low of $52.50 and a 12-month high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.09 by $0.25. The company had revenue of $148.30 million for the quarter, compared to analyst estimates of $144.37 million. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. ANI Pharmaceuticals's revenue was up 12.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.05 earnings per share. On average, analysts forecast that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on ANIP shares. Truist Financial increased their target price on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a "hold" rating in a research note on Tuesday, October 22nd. StockNews.com raised ANI Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Wednesday, February 5th. HC Wainwright reissued a "buy" rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a report on Monday, November 11th. Leerink Partnrs upgraded shares of ANI Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday, December 11th. Finally, Leerink Partners assumed coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, December 11th. They issued an "outperform" rating and a $80.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $77.71.

Insider Buying and Selling at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, CEO Nikhil Lalwani sold 33,481 shares of ANI Pharmaceuticals stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total value of $1,941,563.19. Following the completion of the sale, the chief executive officer now owns 370,378 shares in the company, valued at $21,478,220.22. The trade was a 8.29 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Krista Davis sold 1,000 shares of the firm's stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $60.00, for a total transaction of $60,000.00. Following the completion of the sale, the senior vice president now directly owns 49,059 shares in the company, valued at $2,943,540. This represents a 2.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 42,381 shares of company stock worth $2,441,556. 12.70% of the stock is owned by corporate insiders.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.